San Diego, CA (October 21st) – Cellics announced today that it has received a CARB-X Award of up to US$15 Million to develop a new treatment for sepsis caused by drug-resistant Gram-positive and Gram-negative bacteria. The award will allow Cellics to advance its highly versatile platform to treat not only sepsis but other conditions with unmet medical needs such as post CAR-T Cytokine Release Syndrome (CRS) and COVID-19.
Our Mission
Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines. We strive to develop more effective and safer therapeutics and vaccines for diseases and unmet medical needs.